Abstract
Ibrutinib is a new-targeted therapy that irreversibly and specifically inhibits the Bruton's Tyrosine Kinase (BTK), a key component of the signaling pathways of B cells. The results are very encouraging as monotherapy in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Following the results of recent studies, ibrutinib is now available in France for these three diseases.
Keywords:
BTK inhibitor; Chronic lymphocytic leukemia; Ibrutinib; Inhibiteur de BTK; Leucémie lymphoïde chronique; Lymphome à cellules du manteau; Macroglobulinémie de Waldenström; Mantle cell lymphoma; Waldenström's macroglobulinemia.
Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Adenine / analogs & derivatives
-
Agammaglobulinaemia Tyrosine Kinase
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / metabolism
-
Clinical Trials as Topic
-
Drug Resistance, Neoplasm
-
France
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Lymphoma, Mantle-Cell / drug therapy*
-
Piperidines
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Pyrazoles / pharmacology
-
Pyrazoles / therapeutic use*
-
Pyrimidines / pharmacology
-
Pyrimidines / therapeutic use*
-
Signal Transduction / drug effects
-
Waldenstrom Macroglobulinemia / drug therapy*
Substances
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
ibrutinib
-
Protein-Tyrosine Kinases
-
Agammaglobulinaemia Tyrosine Kinase
-
BTK protein, human
-
Adenine